PLRX Live signals | Maximize Profits with Getagraph.com

BUY 88562 min ago

@ $16.43

Issued: 14 Feb 2024 @ 15:44

Return: -17.50%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 5.47 %

Live Chart Being Loaded With Signals

Commentary (15 Apr 2024 @ 16:00):

Stats
Today's Volume	259 874
Average Volume	386 517
Market Cap	816.24M
EPS	$-0.690 ( 2024-03-28 )
Next earnings date	( $-0.770 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.93
ATR14	$0.0120 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-23	Lefebvre Eric	Buy	42 900	Common Stock
2024-01-23	Lefebvre Eric	Buy	85 800	Stock Option (Right to Buy)
2024-01-23	Hull Hans	Buy	31 500	Common Stock
2024-01-23	Hull Hans	Buy	63 000	Stock Option (Right to Buy)
2024-01-23	Ouimette Mike	Buy	31 500	Common Stock

INSIDER POWER
67.05
Last 98 transactions
Buy: 2 502 892 \| Sell: 552 083

Volume Correlation

Long: -0.05 (neutral)

Short: -0.97 (very strong negative)

Signal:(43.288) Neutral

Pliant Therapeutics Inc Correlation

10 Most Positive Correlations
PAIC	0.955
CSII	0.935
ADMS	0.932
RESN	0.927
HSKA	0.921
ZGNX	0.918
OLMA	0.915
NATI	0.914
IPW	0.912
SVAC	0.911

10 Most Negative Correlations
NETE	-0.945
BOCH	-0.932
MMAC	-0.914
RAVN	-0.912
SHSP	-0.879
SBBP	-0.876
CFV	-0.873
AMRB	-0.869
ORMP	-0.869
AZTA	-0.861

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pliant Therapeutics Inc Correlation - Currency/Commodity

0.81
( strong )

0.72
( moderate )

0.00
( neutral )

0.72
( moderate )

-0.05
( neutral )

0.23
( neutral )

Pliant Therapeutics Inc Financials

Annual	2023
Revenue:	$1.58M
Gross Profit:	$-261 000 (-16.52 %)
EPS:	$-2.75

Q4	2023
Revenue:	$4.84M
Gross Profit:	$4.38M (90.41 %)
EPS:	$-0.690

Q3	2023
Revenue:	$0
Gross Profit:	$-1.04M (0.00 %)
EPS:	$-0.700

Q2	2023
Revenue:	$248 000
Gross Profit:	$-856 000 (-345.16 %)
EPS:	$-0.700

Financial Reports:

No articles found.

Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.